ROCHESTER, Minn., Oct. 24 (UPI) -- U.S. medical scientists have developed a promising combination therapy for patients with recurrent ovarian cancer that's resistant to platinum therapy.
Mayo Clinic researchers have reported promising interim results from a Phase II trial of the new treatment. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.
Findings from the Phase II consortium clinical trial were presented Tuesday in San Francisco by the study’s primary investigator, Dr. Keith Bible, during the Molecular Targets and Cancer Therapeutics International Conference -- a jointly sponsored symposium of the American Association for Cancer Research, the National Cancer Institute and the European Organization for Research and Treatment of Cancer.
"We are encouraged by the interim results of this trial," said Bible, a Mayo Clinic medical oncologist. "Platinum-resistant ovarian cancer responds poorly to traditional therapies and we've been working toward developing more effective treatments for this disease. This combination looks very promising."
